Abstract
Human T cell leukemia virus type 1 (HTLV-1) is a human retrovirus etiologically associated with adult T cell leukemia/lymphoma and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Only approximately 0.25–4 % of infected individuals develop HAM/TSP; the majority of infected individuals remain lifelong asymptomatic carriers. Recent data suggest that immunological aspects of host–virus interactions might play an important role in the development and pathogenesis of HAM/TSP. This review outlines and discusses the current understanding, ongoing developments, and future perspectives of HAM/TSP research.
Similar content being viewed by others
References
Adaui V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arevalo J, Vanham G, Campos M, Zimic M, Gotuzzo E (2006) SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol 12:456–465
Ali A, Patterson S, Cruickshank K, Rudge P, Dalgleish AG, Knight SC (1993) Dendritic cells infected in vitro with human T cell leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation and tropical spastic paraparesis. Clin Exp Immunol 94:32–37
Araujo AQ, Silva MT (2006) The HTLV-1 neurological complex. Lancet Neurol 5:1068–1076
Aye MM, Matsuoka E, Moritoyo T, Umehara F, Suehara M, Hokezu Y, Yamanaka H, Isashiki Y, Osame M, Izumo S (2000) Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol 100:245–252
Azakami K, Sato T, Araya N, Utsunomiya A, Kubota R, Suzuki K, Hasegawa D, Izumi T, Fujita H, Aratani S, Fujii R, Yagishita N, Kamijuku H, Kanekura T, Seino KI, Nishioka K, Nakajima T, Yamano Y (2009) Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 114(15):3208–3215. doi:10.1182/blood-2009-02-203042
Bangham CR (2000) The immune response to HTLV-I. Curr Opin Immunol 12:397–402
Bangham CR, Osame M (2005) Cellular immune response to HTLV-1. Oncogene 24:6035–6046
Best I, Lopez G, Verdonck K, Gonzalez E, Tipismana M, Gotuzzo E, Vanham G, Clark D (2009) IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. Immunology 128:e777–e786
Bhigjee AI, Bill PL, Wiley CA, Windsor IM, Matthias DA, Amenomori T, Wachsman W, Moorhouse D (1993) Peripheral nerve lesions in HTLV-I associated myelopathy (HAM/TSP). Muscle Nerve 16:21–26
Cook LB, Rowan AG, Melamed A, Taylor GP, Bangham CR (2012) HTLV-1-infected T cells contain a single integrated provirus in natural infection. Blood 120:3488–3490
de The G, Bomford R (1993) An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retrovir 9:381–386
Enose-Akahata Y, Matsuura E, Tanaka Y, Oh U, Jacobson S (2012) Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease. Retrovirology 9:16
Enose-Akahata Y, Abrams A, Massoud R, Bialuk I, Johnson KR, Green PL, Maloney EM, Jacobson S (2013) Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals. Retrovirology 10:19
Furukawa Y, Yamashita M, Usuku K, Izumo S, Nakagawa M, Osame M (2000) Phylogenetic subgroups of human T cell lymphotropic virus (HTLV) type I in the tax gene and their association with different risks for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 182:1343–1349
Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G (1985) Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2:407–410
Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, Berry C, Bushman FD, Taylor GP, Bangham CR (2011) The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood 117:3113–3122
Goon PK, Hanon E, Igakura T, Tanaka Y, Weber JN, Taylor GP, Bangham CR (2002) High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood 99:3335–3341
Goon PK, Igakura T, Hanon E, Mosley AJ, Asquith B, Gould KG, Taylor GP, Weber JN, Bangham CR (2003) High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease. J Virol 77:9716–9722
Goon PK, Biancardi A, Fast N, Igakura T, Hanon E, Mosley AJ, Asquith B, Gould KG, Marshall S, Taylor GP, Bangham CR (2004a) Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J Infect Dis 189:2294–2298
Goon PK, Igakura T, Hanon E, Mosley AJ, Barfield A, Barnard AL, Kaftantzi L, Tanaka Y, Taylor GP, Weber JN, Bangham CR (2004b) Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. J Immunol 172:1735–1743
Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP (1998) Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A 95:7568–7573
Hakoda E, Machida H, Tanaka Y, Morishita N, Sawada T, Shida H, Hoshino H, Miyoshi I (1995) Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. Int J Cancer 60:567–570
Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR (2000) Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 95:1386–1392
Harrington WJ Jr, Sheremata WA, Snodgrass SR, Emerson S, Phillips S, Berger JR (1991) Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retrovir 7:1031–1034
Hayashi D, Kubota R, Takenouchi N, Nakamura T, Umehara F, Arimura K, Izumo S, Osame M (2008a) Accumulation of human T-lymphotropic virus type I (HTLV-I)-infected cells in the cerebrospinal fluid during the exacerbation of HTLV-I-associated myelopathy. J Neurovirol 14(5):459–463. doi:10.1080/13550280802178538
Hayashi D, Kubota R, Takenouchi N, Tanaka Y, Hirano R, Takashima H, Osame M, Izumo S, Arimura K (2008b) Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. J Neuroimmunol 200:115–124
Higuchi I, Nerenberg M, Yoshimine K, Yoshida M, Fukunaga H, Tajima K, Osame M (1992) Failure to detect HTLV-I by in situ hybridization in the biopsied muscles of viral carriers with polymyositis. Muscle Nerve 15:43–47
Hilburn S, Rowan A, Demontis MA, MacNamara A, Asquith B, Bangham CR, Taylor GP (2011) In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. J Infect Dis 203:529–536
Hino S, Yamaguchi K, Katamine S, Sugiyama H, Amagasaki T, Kinoshita K, Yoshida Y, Doi H, Tsuji Y, Miyamoto T (1985) Mother-to-child transmission of human T-cell leukemia virus type-I. Jpn J Cancer Res 76:474–480
Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I (1981) Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 78:6476–6480
Hisada M, Stuver SO, Okayama A, Li HC, Sawada T, Hanchard B, Mueller NE (2004) Persistent paradox of natural history of human T lymphotropic virus type I: parallel analyses of Japanese and Jamaican carriers. J Infect Dis 190:1605–1609
Hollsberg P, Hafler DA (1993) Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 328:1173–1182
Ijichi S, Eiraku N, Osame M, Izumo S, Kubota R, Maruyama I, Matsumoto M, Sonoda S (1989) In vitro modulation of lymphocyte proliferation by prednisolone and interferon-alpha in patients with HTLV-I-associated myelopathy (HAM). J Neuroimmunol 23:175–178
Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M (1986) Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J 5:2883–2888
Ishihara S, Okayama A, Stuver S, Horinouchi H, Shioiri S, Murai K, Kubota T, Yamashita R, Tachibana N, Tsubouchi H et al (1994) Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells. J Acquir Immune Defic Syndr 7:199–203
Itoyama Y, Minato S, Kira J, Goto I, Sato H, Okochi K, Yamamoto N (1988) Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology 38:1302–1307
Iwasaki Y (1990) Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J Neurol Sci 96:103–123
Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M (1996) Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46:1016–1021
Izumo S, Umehara F, Osame M (2000) HTLV-I-associated myelopathy. Neuropathology 20(Suppl):S65–S68
Jacobson S (2002) Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 186(Suppl 2):S187–S192
Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S (1990) Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348:245–248
Jain P, Manuel SL, Khan ZK, Ahuja J, Quann K, Wigdahl B (2009) DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol 83:10908–10921
Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, Lloyd AL, Nowak MA, Nagai M, Kodama D, Izumo S, Osame M, Bangham CR (1999) HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 96:3848–3853
Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osame M, Bangham CR (2000) The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 165:7278–7284
Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW (2008) Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 14:429–436
Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M et al (1991) Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol 3:761–767
Kattan T, MacNamara A, Rowan AG, Nose H, Mosley AJ, Tanaka Y, Taylor GP, Asquith B, Bangham CR (2009) The avidity and lytic efficiency of the CTL response to HTLV-1. J Immunol 182:5723–5729
Kinoshita K, Amagasaki T, Hino S, Doi H, Yamanouchi K, Ban N, Momita S, Ikeda S, Kamihira S, Ichimaru M et al (1987) Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res 78:674–680
Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M (2009) Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol 83:5101–5108
Kira J, Nakamura M, Sawada T, Koyanagi Y, Ohori N, Itoyama Y, Yamamoto N, Sakaki Y, Goto I (1992) Antibody titers to HTLV-I-p40tax protein and gag-env hybrid protein in HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with increased HTLV-I proviral DNA load. J Neurol Sci 107:98–104
Kitze B, Usuku K, Yamano Y, Yashiki S, Nakamura M, Fujiyoshi T, Izumo S, Osame M, Sonoda S (1998) Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101. Clin Exp Immunol 111:278–285
Kiwaki T, Umehara F, Arimura Y, Izumo S, Arimura K, Itoh K, Osame M (2003) The clinical and pathological features of peripheral neuropathy accompanied with HTLV-I associated myelopathy. J Neurol Sci 206:17–21
Kiyokawa T, Yoshikura H, Hattori S, Seiki M, Yoshida M (1984) Envelope proteins of human T-cell leukemia virus: expression in Escherichia coli and its application to studies of env gene functions. Proc Natl Acad Sci U S A 81:6202–6206
Klenerman P, Zinkernagel RM (1997) What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev 159:5–16
Kodama D, Saito M, Matsumoto W, Sabouri AH, Izumo S, Arimura K, Usuku K, Bangham CR, Osame M (2004) Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neuroimmunol 156:188–194
Kramer A, Maloney EM, Morgan OS, Rodgers-Johnson P, Manns A, Murphy EL, Larsen S, Cranston B, Murphy J, Benichou J et al (1995) Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol 142:1212–1220
Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S (1998) Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 161:482–488
Kuroda Y, Takashima H, Ikeda A, Endo C, Neshige R, Kakigi R, Shibasaki H (1991) Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol 238:309–314
LaGrenade L, Hanchard B, Fletcher V, Cranston B, Blattner W (1990) Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 336:1345–1347
Lal RB, Giam CZ, Coligan JE, Rudolph DL (1994) Differential immune responsiveness to the immunodominant epitopes of regulatory proteins (tax and rex) in human T cell lymphotropic virus type I-associated myelopathy. J Infect Dis 169:496–503
Liu SY, Sanchez DJ, Cheng G (2011) New developments in the induction and antiviral effectors of type I interferon. Curr Opin Immunol 23:57–64
Macatonia SE, Cruickshank JK, Rudge P, Knight SC (1992) Dendritic cells from patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. AIDS Res Hum Retrovir 8:1699–1706
Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CR, Asquith B (2010) HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog 6
Makino M, Azuma M, Wakamatsu SI, Suruga Y, Izumo S, Yokoyama MM, Baba M (1999) Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. Clin Diagn Lab Immunol 6:316–322
Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, Cranston B, Maloney E, Welles SL, Blattner WA, Waters D (1999) Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 180:1487–1493
Manuel SL, Schell TD, Acheampong E, Rahman S, Khan ZK, Jain P (2009) Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. J Leukoc Biol 86:1205–1216
Martin F, Castro H, Gabriel C, Adonis A, Fedina A, Harrison L, Brodnicki L, Demontis MA, Babiker AG, Weber JN, Bangham CR, Taylor GP (2012) Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 6:e1675
Maruyama I, Chihara J, Sakashita I, Mizoguchi R, Mori S, Usuku K, Jonosono M, Tara M, Matsumoto M, Niina S, Sonoda S, Yasaki S, Osame M (1988) HTLV-I associated bronchopneumonopathy—a new clinical entity? Am Rev Resp Dis 137:46
Matsuo H, Nakamura T, Tsujihata M, Kinoshita I, Satoh A, Tomita I, Shirabe S, Shibayama K, Nagataki S (1988) Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet 2:1109–1113
Matsuoka M, Jeang KT (2011) Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 30:1379–1389
Matsuura E, Yamano Y, Jacobson S (2010) Neuroimmunity of HTLV-I infection. J Neuroimmune Pharmacol 5:310–325
Matsuzaki T, Saito M, Usuku K, Nose H, Izumo S, Arimura K, Osame M (2005) A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 237:75–81
Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, Bangham CR (2013) Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog 9:e1003271
Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, Hinuma Y (1981) Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 294:770–771
Mochizuki M, Yamaguchi K, Takatsuki K, Watanabe T, Mori S, Tajima K (1992) HTLV-I and uveitis. Lancet 339:1110
Morgan OS, Rodgers-Johnson P, Mora C, Char G (1989) HTLV-1 and polymyositis in Jamaica. Lancet 2:1184–1187
Murata N, Hakoda E, Machida H, Ikezoe T, Sawada T, Hoshino H, Miyoshi I (1996) Prevention of human T cell lymphotropic virus type I infection in Japanese macaques by passive immunization. Leukemia 10:1971–1974
Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M (1998) Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 4:586–593
Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S (2001a) Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 183:197–205
Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S (2001b) Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 50:807–812
Nagasato K, Nakamura T, Shirabe S, Shibayama K, Ohishi K, Ichinose K, Tsujihata M, Nagataki S (1991) Presence of serum anti-human T-lymphotropic virus type I (HTLV-I) IgM antibodies means persistent active replication of HTLV-I in HTLV-I-associated myelopathy. J Neurol Sci 103:203–208
Nakagawa M, Izumo S, Ijichi S, Kubota H, Arimura K, Kawabata M, Osame M (1995) HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1:50–61
Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M (1996) Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol 2:345–355
Nakamura H, Hayami M, Ohta Y, Ishikawa K, Tsujimoto H, Kiyokawa T, Yoshida M, Sasagawa A, Honjo S (1987) Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. Int J Cancer 40:403–407
Nascimento CR, Lima MA, de Andrada Serpa MJ, Espindola O, Leite AC, Echevarria-Lima J (2011) Monocytes from HTLV-1-infected patients are unable to fully mature into dendritic cells. Blood 117:489–499
Ndhlovu LC, Snyder-Cappione JE, Carvalho KI, Leal FE, Loo CP, Bruno FR, Jha AR, Devita D, Hasenkrug AM, Barbosa HM, Segurado AC, Nixon DF, Murphy EL, Kallas EG (2009) Lower numbers of circulating natural killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease. Clin Exp Immunol 158(3):294–299. doi:10.1111/j.1365-2249.2009.04019.x
Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M (1989) Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1:441
Nose H, Kubota R, Seth NP, Goon PK, Tanaka Y, Izumo S, Usuku K, Ohara Y, Wucherpfennig KW, Bangham CR, Osame M, Saito M (2007) Ex vivo analysis of human T lymphotropic virus type 1-specific CD4+ cells by use of a major histocompatibility complex class II tetramer composed of a neurological disease-susceptibility allele and its immunodominant peptide. J Infect Dis 196:1761–1772
Oh U, Grant C, Griffith C, Fugo K, Takenouchi N, Jacobson S (2006) Reduced Foxp3 protein expression is associated with inflammatory disease during human t lymphotropic virus type 1 Infection. J Infect Dis 193:1557–1566
Olindo S, Cabre P, Lezin A, Merle H, Saint-Vil M, Signate A, Bonnan M, Chalon A, Magnani L, Cesaire R, Smadja D (2006) Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol 63:1560–1566
Olindo S, Belrose G, Gillet N, Rodriguez S, Boxus M, Verlaeten O, Asquith B, Bangham C, Signate A, Smadja D, Lezin A, Cesaire R, Willems L (2011) Safety of long-term treatment of HAM/TSP patients with valproic acid. Blood 118:6306–6309
Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031–1032
Osame M, Janssen R, Kubota H, Nishitani H, Igata A, Nagataki S, Mori M, Goto I, Shimabukuro H, Khabbaz R et al (1990) Nationwide survey of HTLV-I-associated myelopathy in Japan: association with blood transfusion. Ann Neurol 28:50–56
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77:7415–7419
Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058–6068
Rahman S, Manuel SL, Khan ZK, Wigdahl B, Acheampong E, Tangy F, Jain P (2010) Depletion of dendritic cells enhances susceptibility to cell-free infection of human T cell leukemia virus type 1 in CD11c-diphtheria toxin receptor transgenic mice. J Immunol 184:5553–5561
Rahman S, Khan ZK, Wigdahl B, Jennings SR, Tangy F, Jain P (2011) Murine FLT3 ligand-derived dendritic cell-mediated early immune responses are critical to controlling cell-free human T cell leukemia virus type 1 infection. J Immunol 186:390–402
Roucoux DF, Wang B, Smith D, Nass CC, Smith J, Hutching ST, Newman B, Lee TH, Chafets DM, Murphy EL (2005) A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis 191:1490–1497
Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, Izumo S, Arimura K, Marshall SE, Usuku K, Bangham CR, Osame M (2004) Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 190:1279–1285
Sabouri AH, Saito M, Usuku K, Bajestan SN, Mahmoudi M, Forughipour M, Sabouri Z, Abbaspour Z, Goharjoo ME, Khayami E, Hasani A, Izumo S, Arimura K, Farid R, Osame M (2005) Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J Gen Virol 86:773–781
Sabouri AH, Usuku K, Hayashi D, Izumo S, Ohara Y, Osame M, Saito M (2008) Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Blood 112:2411–2420
Saito M, Taylor GP, Saito A, Furukawa Y, Usuku K, Weber JN, Osame M, Bangham CR (2001) In vivo selection of T-cell receptor junctional region sequences by HLA-A2 human T-cell lymphotropic virus type 1 Tax11-19 peptide complexes. J Virol 75:1065–1071
Saito M, Higuchi I, Saito A, Izumo S, Usuku K, Bangham CR, Osame M (2002) Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 186:1231–1241
Saito M, Braud VM, Goon P, Hanon E, Taylor GP, Saito A, Eiraku N, Tanaka Y, Usuku K, Weber JN, Osame M, Bangham CR (2003) Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers. Blood 102:577–584
Saito M, Jain P, Tsukasaki K, Bangham CR (2012) HTLV-1 infection and its associated diseases. Leuk Res Treat 2012:123637
Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27
Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14:778–809, table of contents
Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Seki M, Ito Y, Hatanaka M, Hinuma Y, Sugimoto M et al (1987) Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 6:3379–3384
Shirabe S, Nakamura T, Tsujino A, Nishiura Y, Furuya T, Goto H, Suenaga A, Nakane S, Yoshimura T, Nagataki S (1997) Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 151:97–101
Sugimoto M, Nakashima H, Watanabe S, Uyama E, Tanaka F, Ando M, Araki S, Kawasaki S (1987) T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 2:1220
Sugimoto M, Nakashima H, Matsumoto M, Uyama E, Ando M, Araki S (1989) Pulmonary involvement in patients with HTLV-I-associated myelopathy: increased soluble IL-2 receptors in bronchoalveolar lavage fluid. Am Rev Respir Dis 139:1329–1335
Tajima K (1990) The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 45:237–243
Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S (2003) Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 9:29–35
Tanaka Y, Ishii K, Sawada T, Ohtsuki Y, Hoshino H, Yanagihara R, Miyoshi I (1993) Prophylaxis against a Melanesian variant of human T-lymphotropic virus type I (HTLV-I) in rabbits using HTLV-I immune globulin from asymptomatically infected Japanese carriers. Blood 82:3664–3667
Tanaka Y, Tanaka R, Terada E, Koyanagi Y, Miyano-Kurosaki N, Yamamoto N, Baba E, Nakamura M, Shida H (1994) Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol 68:6323–6331
Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP, McNab FW, O'Garra A, Taylor GP, Bangham CR (2012) Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8:e1002480
Taylor GP, Goon P, Furukawa Y, Green H, Barfield A, Mosley A, Nose H, Babiker A, Rudge P, Usuku K, Osame M, Bangham CR, Weber JN (2006) Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology 3:63
Terada K, Katamine S, Eguchi K, Moriuchi R, Kita M, Shimada H, Yamashita I, Iwata K, Tsuji Y, Nagataki S et al (1994) Prevalence of serum and salivary antibodies to HTLV-1 in Sjogren's syndrome. Lancet 344:1116–1119
Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CR (2008) High frequency of CD4+ FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood 111:5047–5053
Toulza F, Nosaka K, Tanaka Y, Schioppa T, Balkwill F, Taylor GP, Bangham CR (2010) Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells. J Immunol 185:183–189
Uchiyama T (1997) Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 15:15–37
Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H (1977) Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50:481–492
Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E (2007) Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 7:266–281
Vine AM, Witkover AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE, Bunce M, Eiraku N, Izumo S, Usuku K, Osame M, Bangham CR (2002) Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 186:932–939
Vine AM, Heaps AG, Kaftantzi L, Mosley A, Asquith B, Witkover A, Thompson G, Saito M, Goon PK, Carr L, Martinez-Murillo F, Taylor GP, Bangham CR (2004) The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol 173:5121–5129
Yamano Y, Takenouchi N, Li HC, Tomaru U, Yao K, Grant CW, Maric DA, Jacobson S (2005) Virus-induced dysfunction of CD4+ CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 115:1361–1368
Yoshida M, Seiki M, Yamaguchi K, Takatsuki K (1984) Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 81:2534–2537
Yoshioka A, Hirose G, Ueda Y, Nishimura Y, Sakai K (1993) Neuropathological studies of the spinal cord in early stage HTLV-I-associated myelopathy (HAM). J Neurol Neurosurg Psychiatry 56:1004–1007
Yu F, Itoyama Y, Fujihara K, Goto I (1991) Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis-decrease in NK cell subset populations and activity in HTLV-I seropositive individuals. J Neuroimmunol 33:121–128
Acknowledgment
The author thanks the Ministry of Health, Labor and Welfare, Japan (Health Labour Sciences Research Grant on Intractable Disease, ref H22-013 and H23-126) and the Japan Society for the Promotion of Science (JSPS) (Grant-in-Aid for Scientific Research, ref 21590512 and 24590556), and the Novartis Foundation (Japan) for the Promotion of Science for financial supports.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saito, M. Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis. J. Neurovirol. 20, 164–174 (2014). https://doi.org/10.1007/s13365-013-0192-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13365-013-0192-8